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The role of complement and the mechan ism of su lfone action in derm atitis herpetiform is 
(DH) have not yet been established; prior studies have presented conflicting data regarding 
the effect of sulfones on complement activation and deposition. Thirty-eight DH patients 
were studied. Twenty-four of 25 periles ional skin biopsies and 50 of 67 normal-appearing skin 
biopsies showed the third component of complement (C3) deposited in areas corresponding to 
those of IgA deposition. Nine of 10 patients with bound C3 in normal-appearing and 
perilesional skin during periods of active disease continued to have C3 in . normal-appearing 
skin when treatment with sulfones kept them completely free of lesions for 2 to 8 weeks. When 
either Hartley-strain or C4-deficient guinea pigs were given up to 150 mg/kg sulfoxone (a 
water-soluble su lfone) intraperitoneally for 8 days before elicitation of active Arthus, reverse 
passive Arthus reactions, or Forssman shock, there was no difference in time course, charac-
ter, or intensity of reactions when compared to saline-treated control animals. We were there-
fore unable to demonstrate any effect of sulfones on complement deposit ion in DH skin or on 
complement activation in classical or alternate complement pathway-mediated guinea-pig 
reactions. 
The mechanism(s) by which sulfones act to al-
leviate the symptoms of dermatitis herpetiformis 
(DH) has not yet been established. While sulfones 
have no effect on IgA deposition in DH skin, prior 
studies have presented conf1icti ng data regarding 
their interference with activation and deposition of 
complement. Provost and Tomasi [1] demon-
strated the third component of complement (C3) 
in sites corresponding to those of IgA deposition in 
the per il es iona l skin of untreated patients with 
DH. No C3 deposits were found in the normal 
skin of 5 patients with ddpsone- induced inactive 
disease, although IgA was still present. These 
findings conflict with those of Seah et al [2 ] who 
demonstrated C3 deposits in DH skin irrespective 
of whether clinically involved or uninvolved skin 
was examined or whether the patients were on 
therapy. 
In vitro and animal studies have suggested that 
sulfones interfere with complement-mediated re-
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D-E: derm al-epidermal 
DH: dermati tis herpetiformis 
id: intraderm ally 
ip: intraperitoneally 
iv : intravenously 
OVA: ovalbumin 
PBS: phosphate- buffered saline 
actions. In a preliminary communication, Millikan 
and Conway [3 ] showed that dapsone blocks inu-
lin-induced white cell degranulation and suggested 
that it interferes with complement activation via 
the a lternate pathway . Thompson and Souhami 
[4] showed that prolonged oral administration of 50 
mg/day of dapsone to Hartley-strain guinea pigs 
suppressed the Arthus reaction, a complement-
mediated phenomenon. 
The present study was designed (1) to further 
investigate the possible role of complement in DH 
skin , (2) to resolve the controversy of whether 
sulfones have an effect on complement deposition 
in DH skin , and (3) to extend previous animal work 
to study the effect of sulfones on various classical 
and alternate complement pathway- mediated gui-
nea-pig reactions. 
HUMAN STUDIES 
Patients. Thirty-eight unrelated Caucasian patients, 
aged 15 to 73 years, were studied. Each met the clinical, 
histologic, and therapeutic (sulfones or sulfapyridine) 
diagnostic criteria [or DH [5], and all biopsies showed 
IgA deposits in either the dermal papillae, just beneath 
the dermal- ep idermal (D- E) junction, or in a continuous 
band along the D- E junction [6], regardless of the degree 
of clinical activity of the patients. 
In vivo complement deposition. Direct immunofluores-
cence for in vivo-bound immunoglobulins and comple-
ment components was performed using previously de-
scribed techniques and reagents [7]. All but one of the 
perilesional skin biopsies taken from 23 patients showed 
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C3 d e posits in areas corresponding to t hose of IgA. In 50 
of 67 biopsies ta ken from the norma l-a ppearing skin of 31 
of the patients C3 was found. C5 was seen in at least one 
of t h e biopsies obta ined from 29 of 37 patients studied. 
B iop s ies from 34 pat ients were tested for C1q a nd C4 
depos ition ; all were negative. Properdin and factor B 
were demonstra ble in a t least one biopsy from 2 and 4 
p a tie n ts, respect ively, of t he 39 patients studied. 
O f the patients whose skin biopsies were s tudied when 
t hey were off treatment, 13 had C3 deposited in both 
n orm a l-appearing a nd per iles iona l skin. "fwo addi t iona l 
p ati e nts had C3 deposited in either periles iona l or 
n ormal-appearing skin . One patient who had no lesions 
for 4 mont hs and was neit her taking a ny medication nor 
a dhering to a gluten-free diet had C3 deposited in his 
n ormal -appearing skin . 
Effect of sulfones on complem ent deposit ion. T en 
p atie n ts who had C3 bound in vivo in norm a l-appearing 
a nd p erilesiona l skin had ei ther no prior thera py wi t h 
sulfo n es or sulfa pyridine, or had been off t reatm ent for at 
least 1 week a nd were developing ma ny new lesions when 
their skin biopsies were taken. N ine of the patients 
continued to have C3 deposits in norm a l-a ppearing skin 
w h e n treated wi t h sulfones a nd compl etely free of lesions 
a nd c rusts for at leas t 2 a nd , in some cases, up to 8 weeks . 
One patient who had been free of lesions a nd off 
t reatment for 4 months had C3 deposited in normal-
a ppearing skin both before and after 5 weeks of dapsone 
t h e r a p y (3 weeks of 100 mg daily and 2 weeks of 200 mg 
daily). 
Quantitative C3 levels . Sera were obta ined from 9 
p ati e nts during the active and sulfone- induced inactive 
phases of their d isease. The se ra were stored a t - 20°C 
a nd assayed for B ,C/B ,A by radi a l immunodiffusion f8 ] 
usin g comm ercia lly prepar ed immunoplates (Hyland 
Labs . , Costa Mesa, Calif.) . The serum C3 levels of 
p a ti e nts on a nd off treatment were all within norma l 
limits (62- 212 mg/dl) except for one sample which had a 
leve l of 270 mg/dl. The levels in 3 pat ients increa ed 
slig h t ly, decreased slightly in 1 pa tient, decreased ma rk-
edly in 1 patient, a nd did not cha nge in 4 patients after 
t hey w ere cont rolled wi th sulfone therapy. 
ANIM AL ST UDlES 
A nimals. Female Ha rtley-stra in a nd C4-defi cient 
guinea pigs, weighing 300 to 400 gm, were obta ined from 
t h e Division of Research Services, Veterin a ry Research 
Bra n c h, Sma ll Anim a ls Section, NIH . 
Tre atment. Sulfoxone powder (Abbott, lot no. 
52-94 9 CA) was dissolved in phosphate- buffered sa line 
(PBS) to a concentration of 1 gm/ dl. Do es of 5, 60, or 150 
rng/kg were given intra peritoneally (ip) da ily to groups of 
5 a nimals. T he only dosage producing signifi ca nt anemi a 
a n d m ethemoglobinemi a was 150 mg/ kg. 
Active Arthus reaction. The active Arthus reaction was 
carri e d out in 24 H a rt ley and in 12 C4-defi cient guinea 
pigs. The anim a ls were immuni zed wi th an emulsion of 
equa l volumes of ovalbumin (OVA ) a nd Freund 's com-
plete adjuvant, a to tal dose of 100 Ilg OVA injected in to 
t h e f o ur foot pads . On day 7 after immuniza tion , one-ha lf 
of t h e Ha rt ley stra in a nim a ls were t reated da ily with 150 
, rng/k g sulfoxone ip for 8 days. The other ha lf received 
equiva lent volumes of PBS ip every day for 8 days. The 
sam e procedure was carried ou t wi t h C4-defi cient guinea 
pigs . On day 14 the anima ls were chall enged wi th 0. 1 ml 
in t raderm al (id) injec tions of 100 Ilg of OVA in PBS. The 
anima ls were observed at 1, 4, 8, and 24 hr. 
The re were no differences in the developm ent and 
progr ess ion of the cutaneous reac tions a mong the P BS-
EFFECT OF SULFON ES ON COMPLEMENT 689 
T ABLE. Average values of hemoglobin and 
methem oglobin or hematocrit for the various groups 
Hartl eys HGB Methemoglob in (gm %) (gm %) 
PBS 12.5 1.9 
Sulfoxone 10.4 4.7 
C4·Deri cient HCT (%) 
PBS 43 .8 
Sulfoxone 37.0 
and sulfoxone-t rea ted Ha rtleys, a nd a mong the PBS- and 
su lfoxone-t rea ted C4-defici ent guinea pigs . All of the 
anim a ls had t he onset of edema, erythema, a nd hemor-
rhage wi t hin 2 hr. This reaction increased in in tensity for 
8 hr , a nd by 24 hr necros is had occurred in many of t he 
anim a ls. Skin biopsies of PBS- and ul foxone-treated 
a nim a ls 2 a nd 4 hr afte r skin testing showed similar 
Arthus-type pathology, a lthough t he in te nsity of t he 
reaction was mu ch greater at 4 hr than at 2 hr. Blood was 
drawn at 24 hr by in tracardi ac puncture for hematocri t 
a nd methemoglobin levels. T he average values of hemo-
globin a nd methemoglobin or hematocrit for t he va rious 
groups a re s hown in the T a ble. 
Reverse passive Arthu.s (RPA) . Ant isera to OVA were 
prepared in fe ma le H artley guinea pigs a nd in New 
Zea la nd white ra bbits by 3 subcutaneous injections of 1 
mg OVA in FCA at 2-week in te rva ls. Sera were obta ined 
and pooled 1 week after the last immuni zation. Ant ibody 
t iters of the pooled antisera were measured by the 
Ouchterlony double diffusion in aga r gel tec hnique. Eac h 
pool had a precipi tati ng a nt ibody tite r of 64. The RPA 
reaction was carried out in two groups of Hart ley (5 each) 
and two groups of C4-defi cient (10 each) guinea pigs. One 
group of each was t reated wit h 150 mg/ kg sulfoxone ip 
daily for 8 days, t he other group with equi va lent volumes 
of PBS. On day 8 the a nim a ls were given either 0. 1 ml id 
injections of varying concen t rations of ra bbi t anti -OV A 
antiserum in the left flank a nd of control rabbit serum in 
the right fl ank or 0.1 ml id injections of varyi ng concen-
t rat ions of pooled guinea-pig ant i-OVA ant iserum in to 
the left fl ank a nd cont rol guinea- pig serum in to the right 
fl ank . These concentrations were predetermined so t hat 
gradations from strong to imperceptibl e reactions were 
expected. All a nima ls were immediate ly injected in t rave-
110usly (iv) wi t h 1 ml of OVA in PBS (2 mg/ ml ). The 
a nim a ls were observed at 2, 4, a nd 6 hr for evid ence of 
edema, erythema, hemorrhage, a nd necrosis. 
There were no differences in t he development a nd 
progression of the RPA reaction a mong t he P BS- a nd 
sulfoxone-treated H ar t leys, a nd among the PBS- and 
sulfoxo ne-treated C4 -defi cient gu inea pigs. Hemorrhage 
developed in all of the a nim als within 2 hI' at the s ites of 
ant iserum inject ion when the concentration was 1: 10 or 
greater. At lower concent rations, erythe ma was t he 
earliest skin change . This progressed to hemol'rhage in 
most of the a nima ls at 4 or 6 hr . All control sites were 
negative. 
The average hematocri t of t he anima ls at 24 hr was as 
follows: PBS-45.7%; sulfoxone- 39.4%. 
Forssman reaction . The Forssman reaction occurs only 
in anim als wi t h an in tac t class ical complement pathway. 
An t i-Forssma n a nt iserum was prepared and the reaction 
was carried out in H art ley guinea pigs according to the 
method of May and Fra nk [9 J. E ight H artley-stra in 
a nima ls were divided in to two groups. Four a nim a ls were 
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t reated with 150 mg/kg su lfoxone ip da ily for 8 days; the 
other 4 were left untreated . On day 8 twice the LD •• dose 
(0.2 ml) of anti -Forssman antiserum was injected iv. 
All the anim als in both the untreated and sulfoxone-
treated groups man ifested the typical signs of Forssman 
shock-ruffling of hair, coughing, nose sc'ratching, con-
vulsions, respiratory clusters, and death-within 3 to 5 
min of receiving anti -Forssman antiserum. 
DISCUS ION 
Knowlege of the mechanism(s) of action of 
sulfo nes would undoubted ly increase our under-
standing of t he pathophysiology of DH. An attrac -
tive hypothesis has been offered over t he past few 
years which proposes that sulfones block comple-
ment activation and deposition [1-4 ]. Later accu-
mulation of neutrophils at the dermal papillary 
t ips which may result from chemotactic factors of 
t he complement cascade would t herefore not occur 
during sulfone treatment. 
Prior studies have presented confl icting data 
with regard to complement deposition in skin of 
patients who have been cleared of active disease 
with sulfone therapy [1 ,2 ]. In t his study, C3 was 
seen in normal-appearing as well as periles iona l 
skin of patients with active disease, and in normal-
appearing skin of patients completely free of 
lesions for 2 to 8 weeks. T his is in keeping with the 
findings of Seah et al [2] but in contrast to t hose of 
Provost and Tomasi [1] in that the latter investiga-
tors were unable to detect C3 in any normal -
ap pearing skin whether or not the patients had 
active or inactive disease (T. Provost, personal 
communication, 1975) . This discrepancy is pro-
bably explicable on the basis of the antisera used 
by Provost and Tomasi. Indeed, the antibody 
activi ty of their f1uoresceinated an tibody to C3 was 
less than the one used in th is study. Using our 
antisera, Provost is able to demonstrate C3 in 
normal-appearing skin of patients with DH (per-
sona l com munication , 1975). However, it may be 
t hat weaker antisera may detect more subtle 
changes in C3 deposition in DH skin. This possibil-
ity was not resolved by the current study. The 
quantitative serum C3 levels were within normal 
l imi ts and showed no uniform changes after sulfone 
treatment. 
T he animal studies fai led to detect any effect of 
su lfoxone on complement-mediated guinea-pig 
reactions either in Hartley-strain guinea pigs, 
which have intact classical and alternate comple-
ment pathways, or in C4-deficient guinea pigs, 
which have an intact alternate but inoperative 
classica l pathway. Each group of sulfoxone-treated 
animals had anem ia or methemoglobinemia or 
both, thus demonstrating a pharmacologic effect in 
the animals tested. It may be that su lfoxone or the 
metaboli te which is responsible for its effect in DH 
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is not utilized or formed in the guinea-pig as it is in 
man. However, it seems that t he metabolite which 
causes methemoglobin formation and hemolysis of 
human red blood cells [10,11] is produced in guinea 
pigs. The lack of effect of sulfoxone on t he Arthus 
reaction is not in keeping with a previous study by 
Thompson and Souham i in which 50 mg of dapsone 
given by mouth over a prolonged period of time to 
Hartley-strain gu inea pigs appeared to suppress 
the reaction [4]. Thei r conclusions were based on 
the find ing t hat no hemorrhage was noted in any of 
the reactions in t heir dapsone-treated an imals, 
whereas one-third of the nontreated animals had 
hemorrhagic reactions [4]. Further, it was on ly 
after t he t hird skin test cha llenge t hat edema was 
sign ificantly less in the dapsone-treated animals 
[4]. The dapsone did not affect t he antibody levels 
in t heir animals . All of our animals were treated for 
at least 8 days with a high dosage of su lfoxone. 
T his would be enough time to expect an effect on 
complement activation if t his were its mechanism 
of action. We were unable to demonstrate any ef-
fect of su lfones on complement deposition in DH 
skin or on complement activation in class ica l or al-
ternate complement pathway-mediated guinea-pig 
reactions. 
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